NDAORALTABLETPriority Review
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
7/8 — Comprehensive
Priority Review
JOURNAVX (suzetrigine) by Vertex Pharmaceuticals is sodium channel antagonists [moa]. Approved for sodium channel blocker [epc]. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JOURNAVX (suzetrigine) is an oral small-molecule sodium channel antagonist approved by the FDA on January 30, 2025, for pain management. It blocks sodium channels to reduce pain signal transmission. Patients with chronic pain conditions seeking an oral alternative to existing analgesics are the primary target population.
Growth14.5 years to LOE
Early-stage growth product with emerging market presence; Vertex is building out pain-focused commercial infrastructure with 7 linked job openings.
Mechanism of Action
Sodium Channel Antagonists
Pharmacologic Class:
Sodium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Started Jul 2026
75 enrolled
Knee ArthritisKnee Osteoarthritis
Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery
Started Jul 2026
120 enrolled
Pelvic Organ Prolapse (POP)Stress Urinary Incontinence (SUI)Postoperative Pain
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
Started May 2026
18 enrolled
Pain
Evaluation of Pain Treatment After Total Knee Arthroplasty
Started Apr 2026
60 enrolled
Pain
Suzetrigine for Non-Mastectomy Breast Surgery
Started Apr 2026
120 enrolled
Pain, Acute PostoperativeBreast Disease
Worked on JOURNAVX at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.